41 results about "Functional diarrhea" patented technology

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and / or secretion and / or abdominal disorders or diseases and / or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

The invention relates to a method of decreasing intestinal motility in a subject in need of treatment. The method comprises administering to the subject a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of decreasing intestinal motility in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. In certain embodiments, the subject is a subject with a functional bowel disorder, such as IBS, functional abdominal bloating, or functional diarrhea.

A method for preventing and / or treating a functional gastrointestinal disorder, comprising administering, to a subject with the functional gastrointestinal disorder, rifaximin as an effective ingredient. The functional gastroinstestinal disorder includes a functional esophageal disorder, a functional gastroduodenal disorder (e.g., a functional dyspepsia), a functional bowel disorder (e.g., a functional bloating, a functional diarrhea), a functional abdominal pain syndrome, a functional gallbladder and Sphincter of Oddi disorder, a functional anorectal disorder (e.g., a functional fecal incontinence, a functional anorectal pain, a functional defecation disorder), a functional disorder in neonates and toddlers (e.g., an infant functional diarrhea), a functional disorder in children and adolescents (e.g., a childhood functional abdominal pain, a childhood nonretentive fecal incontinence), and other diseases.

The present invention provides probiotic compositions suitable for relieving symptoms associated with gastrointestinal disorders. In particular, the present invention provides compositions and methods to relieve symptoms associated with functional bowel disorders, irritable bowel syndrome, functional diarrhea, functional bloating, and other symptoms.

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and / or secretion and / or abdominal disorders or diseases and / or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and / or secretion and / or abdominal disorders or diseases and / or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

The invention discloses a traditional Chinese medicine composition for treating functional diarrhea. 12 grams, 14-16 grams of fried white peony, 5-7 grams of cicada slough, 3-5 grams of amomum, 8-12 grams of catalpa, 14-16 grams of kudzu root, 8-12 grams of fried skullcap. Decoct it with water to make a decoction and take it orally. The traditional Chinese medicine composition has obvious effect in treating functional diarrhea, and has the effect of nourishing the liver, spleen and kidney at the same time, has low cost, good curative effect, and no toxic and side effects.

The invention discloses a traditional Chinese medicinal formula capable of relieving functional diarrhea. The traditional Chinese medicinal formula mainly comprises the following raw materials in parts by weight: 2-6 parts of cuttle bone, 4-10 parts of fructus evodiae, 6-10 parts of elecampane, 1-3 parts of concha arcae, 6-15 parts of dried alum, 5-12 parts of magnolia obavata, 8-15 parts of rhizoma coptidis, 6-12 parts of nutgall, 14-26 parts of apple vinegar, and 5-12 parts of sesame oil. The traditional Chinese medicinal formula is capable of relieving functional diarrhea with a curative rate of 100%, can improve the poor appetite situation of a patient after taking, not only can relieve the functional diarrhea for the patient, but also can tonify spleen and invigorate stomach. The traditional Chinese medicine formula takes simple and feasible traditional Chinese medicines as raw materials, can become effective rapidly, is free from any toxic or side effects, quickly relieves the pain for the patient, and plays a good effective role for the functional diarrhea due to too strong gastrointestinal function, and too fast gastrointestinal motility.

The invention discloses a compound, namely (2R, 3R)-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxyl-4-oxo-2,3-dihydrobenzopyran-3-yl) methylamino) methyl-2-phenylpropionate. The invention also discloses a preparation method for the compound and the application of the compound as a feed additive. When serving as the feed additive, the compound can specifically promote the growth of intestinal mucosa villus of livestocks, promote the growth of intestinal linings, reduce the intestinal tension and inhibit abnormal peristalsis, can reduce the feed discharging speed of intestinal tracts of the livestocks so as to enhance the digestive absorption of the intestinal tracts to nutritional components, and can obviously increase the daily weight increasing of the livestocks. The reduction of the intestinal tension contributes to water absorption in the intestinal tracts, and plays an obvious role of convergence and reducing functional diarrhea. The compound provided by the invention also has an effect of repairing intestinal mucosa, and can also obviously improve the immunity function of intestinal mucosa and disease resistance of the livestocks.

The invention relates to a traditional Chinese medicine plaster for treating functional diarrhea. The traditional Chinese medicine plaster is prepared from the following raw pharmaceutical materials in parts by weight: 15-20 parts of bupleurum root, 5-10 parts of dried old orange peel, 5-10 parts of nutgrass galingale rhizome, 10-15 parts of atractylodes macrocephala, 5-10 parts of glycyrrhiza uralensis, 5-10 parts of Chinese yam, 15-20 parts of pagoda tree flower, 5-10 parts of fructus psoraleae, 15-20 parts of coninshaped blueberry branchlet and leaf, 10-15 parts of anemarrhena rhizome, 10-15 parts of fleece-flower stem, 10-15 parts of tree peony bark, 5-10 parts of cinnamon, 5-10 parts of coix seed, 5-10 parts of cortex albiziae, 5-10 parts of angelica sinensis, 10-15 parts of corydalis tuber, 5-10 parts of radix linderae, 3-8 parts of prepared rehmannia root, 2-8 parts of wild jujube seed and 5-10 parts of radix platycodi. A traditional Chinese medicine preparation is good in effect on treating functional diarrhea, is simple and easy to use, is free of toxic or side effects and is easily accepted by patients, so that the traditional Chinese medicine preparation is safe and effective for treating functional diarrhea and has good application prospects.

The invention relates to the use of CY in preparing smooth muscle spasmolysis agent, and in preparing medicaments for treating stomach and intestinal spasm colicky pain, intestine excitable syndrome, ulcerative colitis, stomach and intestine dysfunction, and functional diarrhea.